trastuzumab-emtansine T-DM1
Selected indexed studies
- Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. (Br J Cancer, 2020) [PMID:31839676]
- Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. (Expert Rev Anticancer Ther, 2021) [PMID:33245671]
- Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. (Curr Med Res Opin, 2013) [PMID:23402224]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Trastuzumab emtansine: mechanisms of action and drug resistance. (2014) pubmed
- Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. (2020) pubmed
- Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. (2021) pubmed
- Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. (2013) pubmed
- Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis. (2023) pubmed
- Mechanisms of Resistance to Antibody-Drug Conjugates. (2023) pubmed
- Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. (2015) pubmed
- The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. (2021) pubmed
- Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment. (2020) pubmed
- Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. (2020) pubmed